Keywords: biosante, gets, new, elestrin, formulation, patent, specialty
BioSante gets new Elestrin formulation patent
Article | 16 April 2007
Specialty drugmaker Bradley Pharmaceuticals says fellow USA-based BioSante Pharmaceuticals, from which it in-licenses the drug Elestrin (estradiol gel 0.6%), has been ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
